Minimally Invasive Aesthetic Procedures Will Expand International Markets

Key Takeaways

• Strong adoption of AYON system and expansion into China are expected to accelerate revenue growth and increase international market presence.
  
• Strategic hires and cost reduction initiatives enhance sales execution, operational efficiency, and support margin expansion and long-term earnings improvement.
  
• Revenue instability, ongoing losses, market challenges, international risk, and dependence on a few products threaten Apyx Medical's growth, profitability, and long-term stability.

Catalysts

An energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally.

• The recent launch and enthusiastic early adoption of the AYON system-a next-generation, comprehensive body contouring platform-defies broader industry softness, as surgeons seek innovative, workflow-improving minimally invasive solutions. This is likely to accelerate revenue growth and expand operating leverage as commercial adoption ramps in the second half of 2025 and beyond.
  
• The company's expansion into China, supported by a well-connected distribution partner and newly granted market clearance, positions Apyx to capture demand from a large and rapidly growing middle
• and upper-class population seeking aesthetic procedures, boosting international revenue growth over the next several years.
  
• Strategic senior sales hires for North America, Europe, and Asia, each with deep experience in driving adoption of advanced aesthetic devices, are expected to strengthen local sales execution and market penetration, increasing recurring revenue streams and supporting potential improvements in operating margins.
  
• Apyx is poised to benefit from the growing market of patients experiencing skin laxity post-significant weight loss, particularly those on GLP-1 drugs-a demographic that is expanding rapidly and fueling demand for minimally invasive procedures, supporting higher volumes and top-line growth.
  
• Recent cost-reduction and restructuring initiatives have meaningfully improved the company's cash burn and operating expense base, enhancing financial flexibility to invest in product innovation and commercial growth, which should support margin expansion and future earnings improvement.

Apyx Medical Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Apyx Medical's revenue will grow by 12.1% annually over the next 3 years.
• Analysts are not forecasting that Apyx Medical will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Apyx Medical's profit margin will increase from -37.1% to the average US Medical Equipment industry of 12.5% in 3 years.
• If Apyx Medical's profit margin were to converge on the industry average, you could expect earnings to reach $8.2 million (and earnings per share of $0.18) by about August 2028, up from $-17.3 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 28.8x on those 2028 earnings, up from -4.6x today. This future PE is greater than the current PE for the US Medical Equipment industry at 28.0x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.48%, as per the Simply Wall St company report.

Apyx Medical Future Earnings Per Share Growth

Risks

• The company's overall revenue declined year-over-year, primarily from a 29% drop in the OEM segment, and domestic Advanced Energy sales saw stagnant or modest decreases, indicating potential difficulty in maintaining consistent top-line growth-this instability may pressure future revenue and earnings.
  
• Ongoing net losses, with a $3.8 million net loss in Q2 2025 and cash burn albeit reduced, suggest that Apyx has yet to achieve sustainable profitability, and continued high operating expenses, if not offset by strong sales growth, could further delay positive net margins and earnings.
  
• The aesthetic medical device market remains "challenged" with subdued capital equipment spending, and despite early excitement around AYON, there is execution risk if enthusiasm does not translate to sustained adoption as broader customer segments may remain hesitant-potentially resulting in lower-than-anticipated revenue growth and margin pressure.
  
• International expansion, particularly in China, is in a nascent phase; initial sales and partnerships look promising but expose Apyx to heightened geopolitical, regulatory, and market entry risks, which could impact both revenue reliability and international profitability.
  
• The company remains highly reliant on Renuvion and AYON products, with limited mention of further diversification; setbacks such as intensified competition, disappointing clinical outcomes or shifting customer preferences toward non-invasive alternatives may significantly impact Apyx's market share, thereby increasing revenue volatility and risk to long-term margin and earnings stability.

Valuation

• The analysts have a consensus price target of $4.0 for Apyx Medical based on their expectations of its future earnings growth, profit margins and other risk factors.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $65.5 million, earnings will come to $8.2 million, and it would be trading on a PE ratio of 28.8x, assuming you use a discount rate of 8.5%.
• Given the current share price of $2.12, the analyst price target of $4.0 is 47.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.